Gribero (Dabigatran Etexilate)

Gribero is indicated for several thromboembolic conditions in adults.

• Prevention of stroke and systemic embolism in patients with non‑valvular atrial fibrillation.
• Treatment of acute deep vein thrombosis (DVT) and reduction of recurrence risk.
• Treatment of acute pulmonary embolism (PE) and prevention of recurrent PE.
• Secondary prevention of recurrent DVT and PE after initial therapy.
• Prophylaxis of venous thromboembolism in patients undergoing hip or knee replacement surgery (if approved).

The safety profile of Gribero includes a range of observed adverse events, which are generally categorized by frequency.

Common

• Dyspepsia or stomach discomfort.
• Minor bleeding such as gum or nosebleeds.
• Headache.
• Nausea.

Serious

• Major bleeding events (e.g., gastrointestinal, intracranial).
• Allergic reactions including rash or angioedema.

Before initiating Gribero, clinicians should assess several clinical factors to minimize risk.

• Assess renal function; dose adjustment may be needed in impairment.
• Evaluate bleeding risk, including history of gastrointestinal ulcers or recent surgery.
• Use caution in patients with uncontrolled hypertension.
• Avoid in individuals with known hypersensitivity to dabigatran or its excipients.
• Counsel women of childbearing potential about unknown pregnancy safety.
• Review concomitant antiplatelet or NSAID therapy that may increase bleeding.

Gribero can interact with other medicines, affecting its anticoagulant effect or bleeding risk.

Avoid

• Strong P-glycoprotein inhibitors (e.g., quinidine, ketoconazole, itraconazole).
• Concurrent use of other anticoagulants or thrombolytics.

Use with caution

• P-glycoprotein inducers (e.g., rifampin, carbamazepine).
• NSAIDs, antiplatelet agents (e.g., aspirin, clopidogrel).
• Certain antidepressants (e.g., SSRIs, SNRIs) that may increase bleeding.